Pramlintide

Pramlintide is a 37-amino acid synthetic analog of human amylin (islet amyloid polypeptide, IAPP), a neurohormone co-secreted with insulin by pancreatic beta cells following nutrient ingestion. In type 1 diabetes, amylin secretion is virtually absent alongside the loss of insulin secretion; in type 2 diabetes it is progressively reduced as beta-cell function declines. Pramlintide replaces this deficient signal through three coordinated physiological actions.

First, it suppresses inappropriate postprandial glucagon secretion from pancreatic alpha cells via a neuroendocrine pathway. In healthy physiology glucagon is normally suppressed after meals; this response is blunted in diabetes and contributes substantially to postmeal hyperglycemia.

Second, pramlintide delays gastric emptying, slowing the rate at which ingested carbohydrates transit to the small intestine and enter the circulation. This attenuates the postprandial glucose excursion without meaningfully altering fasting glucose levels.

Third, pramlintide promotes satiety by activating amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem. Amylin receptors are heterodimeric complexes of the calcitonin receptor and receptor activity-modifying proteins (RAMPs); their activation reduces ad libitum food intake through vagal efferent and hypothalamic signaling pathways.

Endogenous amylin self-aggregates into fibrils at pharmaceutical concentrations, making it unsuitable for injection. Pramlintide incorporates proline substitutions at positions 25, 28, and 29 that prevent fibril formation. Subcutaneous bioavailability is approximately 30-40%; half-life is approximately 48 minutes, with peak plasma concentration occurring roughly 20 minutes after injection. The primary metabolite, Des-lys1 pramlintide, retains biological activity.

Pramlintide received US FDA approval in 2005 (NDA 021332, marketed as Symlin) as an adjunct to mealtime insulin for adults with type 1 and type 2 diabetes. It remains the only approved amylin analog and one of very few non-insulin adjuncts with a specific regulatory indication for type 1 diabetes in the United States. Pivotal controlled trials submitted to the FDA enrolled 2,333 patients with type 1 and 1,852 patients with type 2 diabetes across studies of 26-52 weeks duration.

In the pivotal type 1 diabetes trials, pramlintide reduced postprandial plasma glucose concentrations by approximately 3.4-5 mmol/L at 2 hours and produced weight reductions of 1.4-1.6 kg versus slight weight gains (0.1-0.3 kg) in placebo groups. Single-dose studies documented approximately 21-23% placebo-corrected reductions in ad libitum caloric intake.

A 2017 systematic review and meta-analysis (PMC5630431) pooling 10 randomized placebo-controlled trials in type 1 diabetes (n=1,978 pramlintide, n=1,319 placebo) found significant HbA1c reductions of approximately 0.41% at 26 weeks, reduced total daily insulin dose, and lower postprandial glucose. Nausea (RR 2.61), vomiting (RR 1.73), and anorexia (RR 6.29) were the predominant adverse events.

In type 2 diabetes, a pooled post-hoc analysis of two 26-week double-blind randomized controlled trials (n=166; PMID 14617226) showed pramlintide added to insulin produced HbA1c reductions of -0.43% and weight changes of -2.0 kg versus placebo (both p less than 0.001), without increased severe hypoglycemia (0.13 versus 0.19 events per patient-year). A separate pooled analysis in 498 insulin-treated type 2 patients (PMID 15090634) documented placebo-corrected HbA1c reduction of -0.41% and weight loss of -1.8 kg at 26 weeks, with 9% versus 3% of patients achieving 5% or greater weight reduction (p=0.0005).

A 2011 systematic review and meta-analysis of eight randomized trials across type 2 diabetes and obese non-diabetic participants (n=1,616; PMID 21199269) confirmed HbA1c reduction of -0.33% and weight loss of -2.57 kg versus control (both p less than 0.00001).

Typical dosage: 60-120 mcg (with meals).

Pramlintide is injected subcutaneously immediately before major meals, generally defined in prescribing information as meals of more than 250 kcal or 30 g of carbohydrate. It must never be mixed in the same syringe as insulin and must be injected at a separate site.

• Type 1 diabetes: Initial dose is 15 mcg before each major meal. Titrate in 15 mcg increments every 3 days as tolerated (in the absence of clinically significant nausea) to a target maintenance dose of 30-60 mcg per meal. • Type 2 diabetes: Initial dose is 60 mcg before each major meal. After 3 days without significant nausea, increase to 120 mcg per meal. If nausea develops at 120 mcg, reduce back to 60 mcg. • At initiation in both populations, premeal (mealtime) insulin doses must be reduced by 50% to mitigate the risk of insulin-induced hypoglycemia. Subsequent insulin adjustments are individualized through self-monitored blood glucose data. • Pramlintide is available as prefilled pen injectors: Symlin Pen 60 (1.5 mL, 1000 mcg/mL) and Symlin Pen 120 (2.7 mL, 1000 mcg/mL). • Preferred injection sites are the abdomen or thigh. Arm injection produces 20-36% higher and more variable exposure in obese patients and is generally not recommended. • Pramlintide and insulin must be injected at separate anatomical sites for the same meal.

This information is provided solely for educational reference and does not constitute medical advice. Pramlintide is a prescription-only agent requiring individualized dosing, insulin adjustment, and close glucose monitoring under the supervision of a qualified healthcare provider.

Lyophilized (before reconstitution)

Refrigerate 2–8°C before first use. Do not freeze. Protect from light in the original carton.

Reconstituted

Symlin / SymlinPen: once in use, the pen is kept at room temperature (≤30°C) and discarded per the label's in-use table (do not return the pen to the refrigerator after first use).

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

The primary approved and most extensively studied combination is pramlintide added to mealtime insulin, which is the basis of FDA approval for both type 1 and type 2 diabetes. Clinical trials consistently demonstrate additive glycemic benefit and weight reduction versus insulin monotherapy, and this pairing is the reference context for all published efficacy data.

Combination with GLP-1 receptor agonists has been described in a three-patient case series of individuals with type 1 diabetes and obesity (JCEM Case Reports, 2023, luad040). Patients received semaglutide (0.5-1.0 mg weekly) or dulaglutide (4.5 mg weekly) alongside pramlintide (15-60 mcg three times daily). Weight loss of 16.1-23.1% of total body weight was observed over 6-14 months, with stable or improved HbA1c and reduced insulin requirements. The proposed rationale is complementary action on distinct neuronal subpopulations within the brainstem dorsal vagal complex, potentially reducing tachyphylaxis seen with either class alone. This evidence is limited to three patients and must be considered anecdotal; adequately powered randomized trials of this combination have not been published, and benefit attributable to pramlintide versus the GLP-1 agonist alone cannot be established from this data.

The broader scientific rationale for amylin and GLP-1 co-agonism has driven development of cagrilintide plus semaglutide (a distinct, long-acting molecule, not pramlintide) for obesity, which is in active phase 3 clinical investigation as of 2025.

Pramlintide is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Nausea, hypoglycemia risk with insulin

Nausea is the predominant adverse effect and the principal reason for dose reduction or early discontinuation. In the large type 1 diabetes systematic review and meta-analysis (PMC5630431), nausea carried a relative risk of 2.61 versus placebo; vomiting had RR 1.73; anorexia had RR 6.29. In the type 2 diabetes and obesity meta-analysis (PMID 21199269), patients were 1.8 times more likely to report nausea of any severity. Gastrointestinal symptoms are dose-dependent, most prominent during initial titration weeks, and typically diminish with continued use, though consistent long-term resolution data were not uniformly documented across trials.

Severe hypoglycemia carries a boxed warning in the FDA prescribing information. Risk is greatest in type 1 diabetes patients and typically occurs within 3 hours of pramlintide injection when premeal insulin has not been appropriately reduced. The mechanism is insulin action unopposed by adequate nutrient entry due to delayed gastric emptying. A mandatory 50% reduction in mealtime insulin at initiation is required. After insulin doses are appropriately stabilized, severe hypoglycemia incidence in controlled trials approached that of placebo.

Other reported adverse effects include headache, dizziness, fatigue, abdominal pain, and injection site reactions (erythema, bruising, swelling). Isolated post-marketing cases of pancreatitis have been reported.

Absolute contraindications include confirmed gastroparesis (unpredictable gastric motility impedes consistent drug effect) and hypoglycemia unawareness (inability to recognize early symptoms). Relative contraindications or precautions include poor compliance with insulin regimen or blood glucose monitoring, concomitant use of drugs that stimulate gastrointestinal motility, and pediatric age (safety not established). Pregnancy data are limited. No hepatic, renal, cardiovascular, or pulmonary toxicity has been identified in controlled trials up to 52 weeks in duration.